For decades, the investment case for women’s health rested largely on the scale of the unmet need. Women experienced longer diagnostic delays, received treatments developed from incomplete data and lacked effective options across conditions ranging from endometriosis and menopause to cardiovascular and autoimmune disease.
That need remains substantial. But unmet need alone does not create an attractive investment opportunity. As I have written previously, an attractive opportunity begins to emerge when clinical need converges with scientific progress, enabling technology, viable economics and a credible route to commercialisation. This distinction is central to understanding whether women’s health represents an attractive investment opportunity for private wealth.
What makes women’s health increasingly investable today is not simply that the gaps are receiving more attention. Advances in science and technology are changing what can be understood, diagnosed and treated, while demographic and commercial demand is supporting the development of scalable markets.
Women’s health is much broader than reproductive health
Women’s health is frequently treated as a narrow category covering fertility, pregnancy and maternal care. In reality, it includes conditions that affect women uniquely, such as endometriosis and menopause; conditions that present differently in women, including cardiovascular and metabolic disease; and conditions that affect women disproportionately, such as autoimmune disease, osteoporosis and Alzheimer’s disease.
This definition matters from an investment perspective for two reasons. First, it extends the opportunity beyond distinct moments in a woman’s life, such as pregnancy or menopause, to encompass her full life course. The relevant health needs begin in adolescence and continue through the reproductive years, midlife and older age.
Second, women’s health provides a cross-cutting lens across healthcare rather than constituting a single healthcare subsector. The opportunity can be found in biotechnology, medical devices, diagnostics, care delivery, healthcare services and digital health. The underlying businesses therefore may have very different development timelines, regulatory pathways, risk profiles and sources of commercial value.
The market is consequently much larger than the commonly used definition of FemTech suggests. PwC estimates that women’s health already represents a global market of approximately $430–440 billion. This includes around $195–205 billion in core women’s health and a further $235 billion in conditions affecting women differently or disproportionately. PwC projects that the combined market could exceed $600 billion by 2030, representing annual growth of approximately 6–8%.
These figures describe an existing commercial market, not merely a projection of future social need. Demographic change is adding to that demand as populations age and healthcare systems confront conditions that affect women over longer lives.
Science and technology are expanding what is investable
Historically, major gaps in women’s health research limited both clinical understanding and commercial development. Women were underrepresented in clinical studies, sex-specific differences were insufficiently examined and many high-burden conditions attracted limited research funding.
Those constraints have not disappeared, but the scientific and technological environment is changing. Advances in molecular biology, diagnostics, medical devices and data science are making previously overlooked conditions easier to identify and address.
Endometriosis provides one example. Diagnosis has traditionally required invasive procedures and can take years from the onset of symptoms. New diagnostic approaches, including biomarker and saliva-based testing, are creating the possibility of earlier and less invasive detection.
Technology is also improving the understanding of conditions that do not fit neatly within the conventional definition of women’s health. AI-enabled clinical tools can identify patterns that traditional diagnostic pathways may miss, including differences in how cardiovascular disease presents in women. Across healthcare more broadly, more than 1,000 AI-enabled medical devices had received FDA authorisation by January 2025.
The investment opportunity lies in the convergence of unmet clinical need with tools capable of addressing it. Scientific progress creates new products, but technology can also change delivery, reduce diagnostic friction and improve the economics of serving patient populations that existing healthcare systems have handled poorly.
Commercial evidence is beginning to catch up
Women’s health is still an emerging investment category, but it is not an untested one.
Research covering publicly announced transactions between 2000 and 2024 identified more than $90 billion in disclosed exit value across women’s health, with total realised value estimated at up to $100 billion. Ten of the sector’s 23 billion-dollar exits occurred between 2022 and 2024.
The underlying ecosystem is also expanding. More than 4,500 digital FemTech companies are now operating globally, while over 150 venture investors have participated in women’s health and FemTech. According to Silicon Valley Bank, $6.2 billion has been invested since 2019 in companies addressing conditions unique to women, and three of the sector’s five unicorns have emerged since 2024.
This does not mean that every women’s health company represents an attractive investment. A large addressable market cannot compensate for weak clinical evidence, poor unit economics or unrealistic assumptions about adoption and reimbursement. Healthcare businesses remain exposed to scientific failure, regulatory delay, long commercialisation timelines and substantial follow-on capital requirements.
But the evidence does challenge the idea that women’s health is too narrow, too early or too commercially uncertain to warrant serious investment consideration.
From overlooked need to investable opportunity
Women’s health has always contained significant demand. What has changed is the range of solutions that can now be developed and the growing body of evidence that those solutions can produce commercial value.
For investors, the relevant question is therefore no longer whether unmet need exists. It is where scientific progress, enabling technology and viable business models are converging to create attractive investment opportunities.
That distinction is important. Investing in women’s health should not rest on the assumption that underfunding will automatically produce returns. It requires the same discipline as any other healthcare allocation: specialist knowledge, rigorous underwriting and a clear understanding of clinical, commercial and portfolio risk.
For investors who conclude that women’s health merits closer examination, the next step is not immediately to select a fund or company. It is to determine what role the opportunity could play within the portfolio.
Should women’s health become a strategic allocation or remain a source of selected opportunistic investments? Where would the exposure sit within an existing private-markets or healthcare portfolio? Should investors select companies directly, rely on specialist managers or combine several routes? And what expertise, due diligence and governance would each approach require?
These decisions matter because the form of exposure determines which parts of the opportunity an investor can access and which risks ultimately enter the portfolio. I set out the principal routes available in How to Invest in Women’s Health: An Institutional Investor’s Guide. In my next article, I will go further into the trade-offs between those routes, including how investors can decide which form of exposure is appropriate
References
- PwC. From Margin to Mainstream: The Future of Women’s Health. 2026. Read the report.
- World Health Organization. Endometriosis. Updated 2025. Read the fact sheet.
- Bendifallah, S. et al. “Saliva microRNA signature to diagnose endometriosis.” Journal of Clinical Medicine. 2022. View on PubMed.
- Adedinsewo, D.A. et al. “Artificial intelligence guided screening for cardiomyopathies in an obstetric population: a pragmatic randomized clinical trial.” Nature Medicine. 2024. View on PubMed.
- US Food and Drug Administration. FDA Issues Comprehensive Draft Guidance for Developers of Artificial Intelligence-Enabled Medical Devices. 6 January 2025. Read the announcement.
- AOA Dx. Follow the Exits: Why Women’s Health Is a Smart Bet in Healthcare. January 2026. Read the report.
- Silicon Valley Bank. Innovation in Women’s Health 2026. 2026. Read the report.
- Tracxn. FemTech: 2026 Market and Investment Trends. 2026. View the sector data.
- Women of Wearables. 150+ VC Funds Investing in Women’s Health and FemTech. 6 March 2024
